论文部分内容阅读
当管理层低调完成对恒瑞医药的段权收购时,这家研发导向型抗癌医药企业的成长前景及走势逐渐明朗
When the management low-key acquisition of Hengrui completed the acquisition of power, the research and development oriented anti-cancer pharmaceutical companies, the growth prospects and trends gradually clear